Skip to main content
Premium Trial:

Request an Annual Quote

Repeat: May 1, 2001


“I’m particularly skeptical about the use of SNPs to determine whether someone is going to develop a disease or respond or not respond to a drug. The cost of generating SNPs is going to be very low, but the cost of generating phenotypes is going to be very high, and that’s rate limiting.”

David Martin, president and CEO of EOS Biotechnology, speaking at the BIO CEO and Investors Conference in New York City in February


The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.